Onychomycosis Market Size, Share, Opportunities, And Trends By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Others), By Treatment (Oral, Topical, Others), By Distribution Channel (Institutional Sales, Retail Sales), And By Geography - Forecasts From 2025 To 2030

Onychomycosis Market Size:

Onychomycosis Market is anticipated to increase at a 4.56% CAGR, growing from USD 4.733 billion in 2025 to USD 5.915 billion by 2030.

Onychomycosis Market Key Highlights:

• Increasing prevalence of onychomycosis is driving demand for advanced diagnostic and treatment solutions.
• Companies are developing innovative antifungal therapies to improve treatment efficacy and patient outcomes.
• North American market is expanding due to rising geriatric population and higher infection awareness.
• White superficial onychomycosis segment is witnessing rapid growth from improved detection and targeted therapies.

Onychomycosis Market Trends:

Onychomycosis is a contagious disease that influences the nails of the fingers and toes. The onychomycosis market is growing at a rapid pace due to several factors, including the increasing prevalence of the infection. The market is expected to hold a significant value in the coming years, and several companies are investing in the development of new treatments and therapies for onychomycosis. The increasing awareness about the condition and the availability of advanced diagnostic and treatment options are expected to drive the growth of the onychomycosis market in the coming years.

The onychomycosis market deals with the diagnosis, treatment, and management of fungal infections that affect the nails of the fingers and toes. The onychomycosis treatment market is growing rapidly due to the rising prevalence of onychomycosis and the development of advanced diagnostic and treatment methods. The market can be segmented by type, diagnosis, and treatment. The market is expected to hold a significant value in the coming years, and several companies are investing in the development of new treatments and therapies for onychomycosis. However, the stringent regulatory requirements for the approval of new drugs and therapies may negatively impact the growth of the market.

Onychomycosis Market Growth Drivers:

• Increasing Prevalence: The rising pervasiveness of onychomycosis is one of the essential drivers of the market. The condition is normal in both created and non-industrial nations, and the rising occurrence of the disease is driving the interest in cutting-edge analytics and treatment choices.
• Technological Advancements: The improvement of cutting-edge demonstrative and treatment choices is driving the development of the onychomycosis market. The accessibility of innovations, like laser treatment and photodynamic treatment, is working on the adequacy of treatment and diminishing the time expected for treatment.
• Awareness and Education: The rising mindfulness about onychomycosis and its side effects are driving the interest in demonstrative and treatment choices. The accessibility of instructive assets and mindfulness crusades is assisting with expanding mindfulness about the condition and diminishing the disgrace related to it.
• Aging Population: The maturing populace is more defenseless to onychomycosis, and the rising number of old individuals is driving the development of the market. The predominance of onychomycosis in old individuals is confounded by illnesses, for example, diabetes and fringe vascular sickness, which increment the gamble of contamination.
• Psychosocial and Emotional Effects: The psychosocial and profound impacts coming about because of onychomycosis are far-reaching and may fundamentally affect personal satisfaction. The effect of the condition on personal satisfaction is driving the interest in compelling treatment choices that can further develop the physical and close-to-home prosperity of patients.

List of Top Onychomycosis Companies:

• Almirall offers a range of treatments for onychomycosis, including P-3058 (10% terbinafine nail solution). The solution is effective in clinical trials and is expected to be a key product for the company in the coming years.
• Onycho Pharma is developing AMYCOT® a profoundly effectual normally inferred item to treat Onychomycosis (nail parasite). Created utilizing a licensed bioactive concentrate detailing to outfit the counter parasitic properties from the cyanobacteria strain, Arthrospiro Maxima.
• Hexima is developing a new class of antifungal peptides that have broad-spectrum activity against fungal species. The peptides are designed to be safe and effective and have the potential to be a significant advance in the treatment of onychomycosis.

Onychomycosis Market Segmentation Analysis:

• Prominent growth in the white superficial onychomycosis segment within the Onychomycosis Market:

 White superficial onychomycosis is a subtype of onychomycosis that is characterized by white chalky deposits on the surface of the affected nail plate. This subtype is caused by direct invasion of the surface of the nail plate by the fungus, and it can be easily scraped away with a curette or rotary burr. The white superficial onychomycosis segment is witnessing rapid growth due to the increasing incidence of immunocompromised conditions and the rising awareness and diagnosis of fungal nail infections. The increasing prevalence of onychomycosis and the availability of advanced diagnostic and treatment options are expected to drive the growth of the onychomycosis market in the coming years. The most common clinical subtype of onychomycosis is distal lateral subungual onychomycosis, which presents as partial distal onycholysis with subungual hyperkeratosis or crumbling.

Onychomycosis Market Geographical Outlook:

• The North American region is expected to hold a significant share of the Onychomycosis market :

The North American region is expected to hold a significant share of the onychomycosis market due to high drug costs, a rising geriatric population, and an increasing incidence of fungal nail infections. The region has also seen a growing awareness of the vast potential of onychomycosis drugs, which is fueling the market's expansion. Additionally, the rising awareness and diagnosis of fungal nail infections in North America are contributing to the market growth.

Onychomycosis Market Scope:

Report Metric	Details
Onychomycosis Market Size in 2025	USD 1.380 billion
Onychomycosis Market Size in 2030	USD 2.143 billion
Growth Rate	CAGR of 4.56%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Type Treatment Distribution Channel Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Onychomycosis Market	Almirall Onycho Pharma Blue Cross NC Hexima Hallux Inc
Customization Scope	Free report customization with purchase

 

Segmentation

• By Type
  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Others
• By Treatment
  • Oral
  • Topical
  • Others
• By Distribution Channel
  • Institutional Sales
  • Retail Sales
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

Our Best-Performing Industry Reports:

• Healthcare Compliance Software Market
• Healthcare Data Storage Market
• Healthcare Fraud Analytics Market

---

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. ONYCHOMYCOSIS MARKET, BY TYPE

5.1. Introduction

5.2. Distal Subungual Onychomycosis

5.3. White Superficial Onychomycosis

5.4. Proximal Subungual Onychomycosis

5.5. Others

6. ONYCHOMYCOSIS MARKET, BY TREATMENT

6.1. Introduction

6.2. Oral 

6.3. Topical

6.4. Others

7. ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Institutional Sales

7.3. Retail Sales

8. ONYCHOMYCOSIS MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

10.1. Almirall

10.2. Onycho Pharma

10.3. Blue Cross NC

10.4. Hexima

10.5. Hallux Inc

10.6. Bausch Health

10.7. Avalon Healthcare Solutions

10.8. Canesten UK

10.9. Julbliarx

10.10. Ferozsons Laboratories Limited

Almirall

Onycho Pharma

Blue Cross NC

Hexima

Hallux Inc

Bausch Health

Avalon Healthcare Solutions

Canesten UK

Julbliarx

Ferozsons Laboratories Limited